{"id":251492,"date":"2021-08-26T00:00:00","date_gmt":"2021-08-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0042-biopharma-atrial-fibrillation-epidemiology-asia-pacific\/"},"modified":"2026-03-31T10:42:37","modified_gmt":"2026-03-31T10:42:37","slug":"epidcv0042-biopharma-atrial-fibrillation-epidemiology-asia-pacific-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0042-biopharma-atrial-fibrillation-epidemiology-asia-pacific-data\/","title":{"rendered":"Atrial Fibrillation &#8211; Epidemiology &#8211; Asia Pacific Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of atrial fibrillation (<abbr data-abbreviation-entity=\"4724\" title=\"atrial fibrillation\">AF<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"atrial fibrillation\">AF<\/abbr> for each country, as well as annualized case counts projected to the national population. Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years and the patient populations in the other countries under study over 10 years. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities are also forecast across the major pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"atrial fibrillation\">AF<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will change in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"atrial fibrillation\">AF<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"atrial fibrillation\">AF<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"atrial fibrillation\">AF<\/abbr>, how many are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"atrial fibrillation\">AF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least ten years of forecast data for the following <abbr data-abbreviation-entity=\"4724\" title=\"atrial fibrillation\">AF<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases.<\/li>\n<li>Undiagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases by subtype scheme.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases by hypertension status.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases by valvular heart disease status.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases by heart failure status.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> prevalent cases by <abbr title=\"Congestive heart failure, high blood pressure, age 45 or older, diabetes, previous stroke or transient ischemic attack\">CHADS2<\/abbr> score scheme.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> drug-treated prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"atrial fibrillation\">AF<\/abbr> non-drug-treated prevalent cases.<\/li>\n<\/ul>\n<p>\u2026&#8230; and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251492","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-atrial-fibrillation","biopharma-therapy-areas-cardiovascular","biopharma-product-epidemiology","biopharma-geography-asia-pacific","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251492\/revisions"}],"predecessor-version":[{"id":283923,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251492\/revisions\/283923"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}